Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
This is a result of differences in obesity diagnosis rates across states
Aliquot and store at 80 C after reconstitution to avoid freeze-thaw degradation
Why this trial matters: Provides real-world evidence on first-line regimens in a poor-prognosis mCRC subtype Highlights superior survival with chemo + anti-VEGF versus chemo alone or targeted therapy Reinforces the importance of personalized treatment strategies and further trials Eli Lilly Retatrutide Delivers Unprecedented Weight Loss in Phase III TRIUMPH-4 Trial Eli Lillys investigational triple-agonist retatrutide produced an average ~28.7% body-weight reduction (71.2 lbs) at 68 weeks in the Phase III TRIUMPH-4 obesity trial, along with meaningful knee osteoarthritis pain relief, marking one of the strongest weight-loss results reported in late-stage obesity research
This product is not a drug, food, or cosmetic and should not be used as a substitute for medical advice or treatment
US$ 28.89
US$ 28.25
US$ 25.57
US$ 26.63
.png)
